2,2,3,3-Tetrachlor-propionitril | 88917-13-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,2,3,3-Tetrachlor-propionitril
• 英文别名: 2,2,3,3-tetrachloro-propionitrile；2,2,3,3-Tetrachloropropanenitrile
• CAS: 88917-13-9
• 化学式: C₃HCl₄N
• 分子量: 192.86
• InChiKey: JVMLEMPAPMTTLO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2,3,3-Tetrachlor-propionitril 在 甲烷 作用下， 生成 三氯丙烯腈
  参考文献：
  名称：

  Brintzinger; Pfannstiel; Koddebusch, Angewandte Chemie, 1948, vol. 60, p. 312

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-3-氯丙-2-烯腈 在 氯 作用下， 生成 2,2,3,3-Tetrachlor-propionitril
  参考文献：
  名称：

  Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting

  摘要：

  Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) placement is effective in the treatment of complications of portal hypertension. This study evaluated the predictors of mortality in a group of cirrhotic patients with advanced liver disease after placement of TIPS. Methods: A retrospective analysis of all patients undergoing TIPS placement over a 2 1/2-year period was undertaken. Results: Fifty-six patients had TIPS placement for variceal hemorrhage, 49 for refractory ascites, and 24 for hepatic hydrothorax (total, 129). Of 21 variables available before TIPS placement, variceal hemorrhage requiring emergent TIPS placement (relative risk [RR], 37.5; 95% confidence interval [CI], 5.4-259) and bilirubin concentration >3.0 mg/dL (RR, 5.4; 95% CI, 1.4-10.2) were independent predictors of 30-day mortality. Variceal hemorrhage requiring emergent TIPS placement (hazard ratio [HR], 5.1, 95% CI, 2.2-9.1), alanine aminotransferase level >100 IU/L (HR, 2.5; 95% CI, 1.2-5.5), bilirubin level >3.0 mg/dL (HR, 2.6; 95% CI, 1.1-4.6), and pre-TIPS encephalopathy unrelated to bleeding (HR, 2.2; 95% CI, 1.2-4.8) independently predicted death during the follow-up period. A model was developed that separated the patients into 3 groups with significantly different survival rates. Conclusions: A clinical index consisting of 4 pre-TIPS variables can reliably predict outcome after TIPS.

  DOI：

  10.1016/s0016-5085(00)70422-7

文献信息

• 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof
  申请人：DeLuca Hector F.

  公开号：US20070238705A1

  公开（公告）日：2007-10-11

  Compounds of formula I are provided where X 1 , X 2 and X3 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.

  提供式I的化合物，其中X1、X2和X3独立地选择自H或羟基保护基团。这些化合物用于制备药物组合物，并且在治疗各种生物学疾病方面非常有用。
• 2-Methylene-1Alpha,25-Dihydroxy-19,21-Dinorvitamin D3 Analogs and Uses Thereof
  申请人：DeLuca Hector F.

  公开号：US20070238706A1

  公开（公告）日：2007-10-11

  Compounds of formula I are provided where X 1 , X 2 and X 3 are independently selected from H or hydroxy protecting groups. Such compounds are used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.

  提供了化学式为I的化合物，其中X1、X2和X3独立地选择自H或羟基保护基团。这些化合物用于制备制药组合物，并可用于治疗各种生物状况。
• Substituted isoxazoles and their use as antibiotics
  申请人：Farrerons Gallemi Carles

  公开号：US20050014806A1

  公开（公告）日：2005-01-20

  Compounds of formula (I), wherein X is O, S, NH, OCO, NH—CO, NH—COO, NH—CO—NH, NH—CS or NH—CS—NH; R4 is H, (C 1 -C 3 )-alkyl optionally substituted by halogen, or a C-linked heterocyclic radical selected from several possibilities; R1 and R3 are H or F; and R2 is an N-linked or C-linked heterocyclic radical, are useful in the treatment of microbial infections in human or animal body.

  公式（I）的化合物，其中X为O，S，NH，OCO，NH—CO，NH—COO，NH—CO—NH，NH—CS或NH—CS—NH；R4为H，(C1-C3)-烷基，可选地被卤素取代，或从多种可能性中选择的C-连接杂环基团；R1和R3为H或F；R2为N-连接或C-连接的杂环基团，可用于治疗人或动物体内的微生物感染。
• FUNGICIDAL CARBOXAMIDES
  申请人：Basarab Steven Gregory

  公开号：US20060025472A1

  公开（公告）日：2006-02-02

  Compounds of Formula I are disclosed which are useful as fungicides wherein Q is X is —O—, —CH(R 11 )— or ═C(R 11 )—; R 1 is H or C 1 -C 2 alkyl; R 2 is H; C 1 -C 6 alkyl; C 3 -C 6 cycloalkyl; or phenyl optionally substituted with halogen, cyano, C 1 -C 2 alkyl or C 1 -C 2 alkoxy; and R 3 -R 11 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula I and a method for controlling plant diseases caused by fungal plant pathogens which involves applying an effective amount of a compound of Formula I.

  公开了式I的化合物，其可用作杀菌剂，其中Q为X为-O-，-CH（R11）-或═C（R11）-; R1为H或C1-C2烷基; R2为H; C1-C6烷基; C3-C6环烷基; 或苯基，该苯基可选地被卤素，氰基，C1-C2烷基或C1-C2烷氧基取代; R3-R11如所述。还公开了含有式I化合物的组合物以及一种控制由真菌植物病原体引起的植物病害的方法，其中涉及施用有效量的式I化合物。
• Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Edmondson D. Scott

  公开号：US20080009510A1

  公开（公告）日：2008-01-10

  The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种新型的取代融合氨基哌啶，它们是二肽基肽酶-IV酶（“DPP-IV抑制剂”）的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物的用途。